RB1 and non-small cell lung carcinoma: While we could not pinpoint mutations that could serve as markers for beneficiaries of immunochemotherapy in EGFR-mutant NSCLC, we did observe that certain pre-treatment mutations like RBM10 and RB1, which have been previously linked to reduced EGFR-TKI efficacy in EGFR-mutant NSCLC,40,41,42 occurred more frequently in patients achieving MPR after neoadjuvant immunochemotherapy.